Total amount raised
$37.4 Million
Latest funding date
05/01/2024
Location
Nabla Bio has successfully raised funding over 5 rounds, with the latest being a Series A round. The company is backed by 9 investors, including Fifty Years, Khosla Ventures, and Radical Ventures as a lead investor.
Keep reading to explore the intricacies of Nabla Bio's fundraising journey and the investors backing this innovative platform.
What Is Nabla Bio?
Nabla Bio is a biotechnology company based in Cambridge, Massachusetts, specializing in drug development and biopharma. The company operates within the biotechnology, biopharma, and machine learning industries, leveraging proprietary biologically informed machine learning to co-develop antibody drugs.
With an employee count ranging from 11 to 50, Nabla Bio collaborates with leading pharmaceutical companies to maximize the impact of their platform. The company aims to make drug development a designable discipline, reducing trial-and-error to deliver better medicines faster.
How Much Funding Has Nabla Bio Raised?
- Pre-Seed Round
- Amount Raised: USD 125,000
- Date: August 2020
- Lead Investors: Fifty Years
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the development of their proprietary biologically informed machine learning platform.
- Grant
- Amount Raised: USD 256,000
- Date: March 2021
- Lead Investors: National Science Foundation
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support early-stage research and development efforts.
- Pre-Seed Round
- Amount Raised: USD 125,000
- Date: August 2021
- Lead Investors: Fifty Years
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop their machine learning platform and expand their research capabilities.
- Seed Round
- Amount Raised: USD 11,000,000
- Date: December 2021
- Lead Investors: Khosla Ventures, Zetta Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To apply cutting-edge generative models to the design of protein-based therapies.
- Series A Round
- Amount Raised: USD 26,000,000
- Date: May 2024
- Lead Investors: Radical Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand operations and development efforts, and to further develop integrated AI and wet-lab technologies for drug design.
Total Amount Raised: USD 37,506,000. Current Valuation: Not publicly disclosed.
Key Investors
- Radical Ventures
- Details: Radical Ventures is a venture capital firm that led Nabla Bio's $26 million Series A funding round. They focus on investing in companies leveraging artificial intelligence and other advanced technologies.
- Investment Focus Areas: Artificial intelligence, advanced technologies, biotech.
- Notable Investments: Nabla Bio, other AI-driven companies.
- Khosla Ventures
- Details: Khosla Ventures is a venture capital firm that provided initial funding for Nabla Bio. They invest in early-stage companies across various sectors, including technology and healthcare.
- Investment Focus Areas: Technology, healthcare, clean energy, biotech.
- Notable Investments: Square, DoorDash, Impossible Foods.
- Zetta Venture Partners
- Details: Zetta Venture Partners is a venture capital firm that also provided initial funding for Nabla Bio. They specialize in funding early-stage companies that leverage AI and machine learning.
- Investment Focus Areas: Artificial intelligence, data analytics, machine learning.
- Notable Investments: Early-stage AI and data-driven startups.
- Fifty Years
- Details: Fifty Years is a seed fund that backs founders solving the world's biggest problems. They were one of the initial investors in Nabla Bio.
- Investment Focus Areas: Biotech, sustainability, health.
- Notable Investments: Solugen, Memphis Meats.
- National Science Foundation
- Details: The National Science Foundation is a government agency that supports fundamental research and education in all non-medical fields of science and engineering. They provided a grant to Nabla Bio.
- Investment Focus Areas: Science, engineering, education.
- Notable Investments: Various research and development projects.
What's Next for Nabla Bio?
With $26 million in Series A funding and strategic collaborations with pharmaceutical giants like AstraZeneca, Bristol Myers Squibb, and Takeda, Nabla Bio is poised for significant growth. These partnerships, valued at over $550 million in upfront and milestone payments, offer a substantial opportunity to expand their drug pipelines and develop highly selective protein drugs.
Future fundraising rounds are likely as Nabla Bio continues to demonstrate the efficacy of its AI and wet-lab technologies. The company’s focus on challenging targets like multipass membrane proteins positions it well for attracting further investment and potential acquisitions by larger pharmaceutical companies.
However, Nabla Bio faces challenges such as high competition in the biotech industry and technical hurdles in developing and scaling their technologies. Ensuring successful collaborations and navigating regulatory requirements will be crucial for their sustained growth and success.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Nabla Bio and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
